Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Expression of plasminogen activators (PA), tissue type (t-PA) and urokinase type (u-PA), as well as PA inhibitors (PAI), type-1 (PAI-1) and type 2 (PAI-2), were investigated immunohistochemically in 97 human pancreatic carcinomas. u-PA expression predominated in pancreatic carcinomas, compared with t-PA [u-PA expression in 76 specimens (78.4%) and t-PA in eight specimens (8.2%)]. PAI-1 expression was detected in 80 carcinoma specimens (82.5%) and PAI-2 in 79 carcinoma specimens (81.4%). PAI-2 expression was significantly lower in carcinomas with peritoneal metastasis (p < 0.02). Strong PAI-2 expression was associated with significantly higher survival than negative or weak PAI-2 expression (p < 0.05). We conclude that immunohistochemical analysis of PAI-2 expression in pancreatic carcinomas may yield important prognostic information.
Takeuchi
Y
Y
Department of Surgery II, Nagoya University School of Medicine, Japan.
Nakao
A
A
Harada
A
A
Nonami
T
T
Fukatsu
T
T
Takagi
H
H
D000230:Adenocarcinoma / Q000378:metabolism* / Q000401:mortality; D006801:Humans; D007124:Immunoenzyme Techniques; D010179:Pancreas / Q000737:chemistry; D010190:Pancreatic Neoplasms / Q000378:metabolism* / Q000401:mortality; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis*; D017396:Plasminogen Activator Inhibitor 2 / Q000032:analysis*; D011379:Prognosis; D015996:Survival Rate; D010959:Tissue Plasminogen Activator / Q000032:analysis*; D014568:Urokinase-Type Plasminogen Activator / Q000032:analysis*
D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator